🇮🇹 The Associazione Urologi Italiani AURO.it Congress in Genova brings together the Italian urology community to discuss the latest advances shaping the future of this specialty. Visit Fabio Maggioni and Andrea Lorenzo Polo to discover how solutions like QP-Prostate help optimize prostate MRI analysis by reducing inter-reader variability, increasing confidence levels, and supporting more accurate targeting in fusion biopsy procedures. We’d love to connect and exchange views on the future of imaging techniques in urology! #Urology #AIinHealthcare #MedicalImaging
Quibim’s AI-powered imaging biomarkers are already helping pharmaceutical companies predict treatment response, optimize clinical trial selection, stratify risk, and accelerate drug development. With Itta MacNevin joining as Chief Business Officer, we’re ready to go even further. Strengthening our leadership in life sciences marks a key step as we expand our capabilities and support partners in delivering faster, more precise, and more efficient therapies across oncology, immunology, and neurology. Welcome, Itta! https://bit.ly/3OsR0FV #LifeSciences #Innovation #Oncology #Immunology #Neurology
Improving oncology endpoints with AI requires more than just innovation: it demands coordination, robust evidence, and genuine collaboration. 📄 In a recently published white paper, we have joined forces with Friends of Cancer Research, as part of the ai.RECIST initiative, to explore the limitations of current standards and the opportunities AI offers to redefine response assessment. As part of this initiative, our technology—designed to detect, quantify, and automatically track lesions over time—will be evaluated in an upcoming study, with the goal of enabling more precise, consistent, and scalable approaches. #AIinHealthcare #MedicalImaging #ClinicalTrials #CancerResearch #LifeSciences
Today is #WorldHealthDay, and it’s time to face an uncomfortable truth: we’re still too late. Half of all cancers are detected at stages 3 or 4. Autoimmune diseases take, on average, between 5 and 7 years to be diagnosed. And what is the cost of waiting? A 250% to 400% increase due to late detection. Today’s medicine reacts. Tomorrow’s medicine anticipates. At Quibim, we are shifting from precision medicine to precision health, where AI is shaping a future where diseases will be detected before they even exist. Joel Stutz #AIinHealthcare #MedicalImaging #DigitalTwin
The future of radiology is being shaped right now at The British Institute of Radiology Congress. Maria Proud , MHA, Francesca Evans, David Eggleton and Emmanuel L. took this opportunity to connect with the radiology community and demonstrate how AI-based imaging biomarkers are helping to optimize workflows, increase diagnostic reliability, and ultimately improve patient outcomes. 📩 Couldn't meet them? Book a demo here: https://bit.ly/3Q3mkeF #BIRAI2026 #AIinHealthcare #Radiology #MedicalImaging
🇩🇪 We are in Potsdam, Germany, for the final consortium meeting of the European FLUTE Project - AI & Prostate Cancer. This event marks the culmination of three years of progress in applying AI to healthcare. FLUTE has brought together leading partners to leverage federated learning and develop high-impact, privacy-preserving AI that improves the detection of clinically significant #ProstateCancer. At Quibim, we have contributed by extracting quantitative imaging biomarkers from prostate MRI scans at three hospitals by using QP-Prostate®. These biomarkers have fed into the AI models developed by Gradiant. We have also partnered with the UPC to generate and validate synthetic prostate images. We are proud to be part of this journey and the impact that will follow. #AIinHealthcare #Radiology #MedicalImaging #Radiomics
"𝘞𝘩𝘦𝘯 𝘸𝘦 𝘳𝘦𝘷𝘪𝘦𝘸 𝘢𝘯 𝘪𝘮𝘢𝘨𝘦 𝘵𝘩𝘢𝘵 𝘢𝘱𝘱𝘦𝘢𝘳𝘴 𝘯𝘰𝘳𝘮𝘢𝘭 𝘢𝘯𝘥 𝘘𝘶𝘪𝘣𝘪𝘮’𝘴 𝘈𝘐 𝘢𝘭𝘴𝘰 𝘤𝘭𝘢𝘴𝘴𝘪𝘧𝘪𝘦𝘴 𝘪𝘵 𝘢𝘴 𝘯𝘰𝘳𝘮𝘢𝘭, 𝘵𝘩𝘦 𝘱𝘳𝘰𝘣𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘰𝘧 𝘵𝘩𝘦𝘳𝘦 𝘣𝘦𝘪𝘯𝘨 𝘯𝘰 𝘢𝘣𝘯𝘰𝘳𝘮𝘢𝘭𝘪𝘵𝘪𝘦𝘴 𝘪𝘴 𝘷𝘦𝘳𝘺 𝘩𝘪𝘨𝘩. 𝘖𝘯 𝘵𝘩𝘦 𝘰𝘵𝘩𝘦𝘳 𝘩𝘢𝘯𝘥, 𝘪𝘧 𝘵𝘩𝘦 𝘈𝘐 𝘥𝘦𝘵𝘦𝘤𝘵𝘴 𝘢 𝘭𝘦𝘴𝘪𝘰𝘯 𝘸𝘦 𝘮𝘢𝘺 𝘩𝘢𝘷𝘦 𝘰𝘷𝘦𝘳𝘭𝘰𝘰𝘬𝘦𝘥—𝘴𝘶𝘤𝘩 𝘢𝘴 𝘢 𝘗𝘐-𝘙𝘈𝘋𝘚 3 𝘭𝘦𝘴𝘪𝘰𝘯—𝘪𝘵 𝘨𝘪𝘷𝘦𝘴 𝘶𝘴 𝘢𝘥𝘥𝘦𝘥 𝘤𝘰𝘯𝘧𝘪𝘥𝘦𝘯𝘤𝘦 𝘢𝘯𝘥 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘴 𝘢𝘥𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘧𝘰𝘳 𝘰𝘶𝘳 𝘢𝘴𝘴𝘦𝘴𝘴𝘮𝘦𝘯𝘵." As Dr. Jeronimo Barrera Ortega states in this interview, early detection and data-driven healthcare are the areas where artificial intelligence can truly make a difference. #ArtificialIntelligence #ProstateCancer #MedicalImaging #HealthcareInnovation
🇵🇷 At the Society of Abdominal Radiology Annual Meeting in Puerto Rico, we’re showcasing how seamless integration is bringing AI closer to daily clinical practice. Visit Edward Ramirez R.T. (R)(MR) B.S. & Joshua Moss to discover how QP-Prostate® integrates directly into DynaCAD Prostate—delivering quantitative insights within the tools radiologists already use, for more efficient workflows and greater diagnostic confidence. #AIinHealthcare #PrecisionMedicine #ProstateCancer
We're excited to announce, the Retrospective case recruitment has now begun at the Dudley Group NHS Foundation Trust and George Eliot Hospital NHS Trust for our groundbreaking project: "𝘖𝘱𝘵𝘪𝘮𝘪𝘴𝘪𝘯𝘨 𝘗𝘳𝘰𝘴𝘵𝘢𝘵𝘦 𝘊𝘢𝘯𝘤𝘦𝘳 𝘋𝘦𝘵𝘦𝘤𝘵𝘪𝘰𝘯: 𝘐𝘯𝘵𝘦𝘨𝘳𝘢𝘵𝘪𝘯𝘨 𝘘𝘗‑𝘗𝘳𝘰𝘴𝘵𝘢𝘵𝘦 𝘵𝘰 𝘌𝘭𝘦𝘷𝘢𝘵𝘦 𝘌𝘢𝘳𝘭𝘺 𝘋𝘪𝘢𝘨𝘯𝘰𝘴𝘪𝘴 𝘙𝘢𝘵𝘦𝘴 𝘪𝘯 𝘕𝘏𝘚 𝘗𝘢𝘵𝘩𝘸𝘢𝘺𝘴 – 𝘙𝘦𝘢𝘭‑𝘞𝘰𝘳𝘭𝘥 𝘐𝘮𝘱𝘭𝘦𝘮𝘦𝘯𝘵𝘢𝘵𝘪𝘰𝘯 𝘚𝘵𝘶𝘥𝘺." As this phase kicks off, prostate MRIs and clinical data are being sent to the QP‑Insights platform, laying the foundation for evaluating current practice before QP‑Prostate is introduced into routine clinical workflows. This is a major step toward supporting Radiologists with early prostate cancer detection and ultimately improving patient outcomes. Supported by SBRI Healthcare this multi‑Trust study will assess the clinical, economic, and real‑world impact of AI‑enhanced prostate MRI interpretation through to June 2027. Karen Hale | Ravinder Sahota FBCS | Suki Bhutta | Helen Bromage| Sally M. | Jaspreet Kaur | Amritpal Gidda | Fhezan Ashraf | Kiran Randhawa | Claire Phillips | Sarah Brown | Sagar M. | Tom Cook | Sid Singh | Adesina Adesuyi | Alison Bettany | Maria Proud , MHA | Marta Martinez Calle, Ph.D. | David Eggleton | Francesca Evans #AIinHealthcare #NHS #Radiology #EarlyDetection #DigitalHealth
🇬🇧 We are at the European Association of Urology in London. 📍 Want to discover more about how AI-powered imaging analysis is bringing greater precision and efficiency to prostate imaging? Visit us at Booth Q25, Purple Area, Level 0 to meet the team and see our technology in action. #EAU2026 #Urology #AIinHealthcare #PrecisionMedicine #ProstateCancer
